Drug Trial Radar · NCT00912093
A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)
Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
98
Actual
Start
Jul 16, 2009
Primary completion
Oct 1, 2010
Study completion Oct 1, 2010
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 3, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the efficacy and safety of icatibant compared to placebo in patients experiencing acute attacks of hereditary angioedema (HAE).
Conditions
- Hereditary Angioedema
Interventions
IcatibantDrug
Single subcutaneous injection of icatibant, 30 mg
PlaceboDrug
Single subcutaneous injection of matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Onset of Symptom Relief for an Acute Attack, as Assessed by the PatientTime frame: Up to 120 hours post-dose
Locations
64 sites in 9 countries. Site status is shown where the registry gives one.
Primary Care Associates of Alabaster
Alabaster, Alabama
UAB Lung Health Center
Birmingham, Alabama
Medical Research of AZ A Division of Allergy & Immunology Assoc
Scottsdale, Arizona
Little Rock Allergy & Asthma Clinic, PA
Little Rock, Arkansas
Allergy and Asthma Insititute of the Valley
Granada Hills, California
University of California San Diego
La Jolla, California
UCLA - Clinical Immunology & Allergy
Los Angeles, California
Speciality Medical Clinic & Research Center
Stanford, California
Standford University
Stanford, California
Asthma & Allergy Associates, PC
Colorado Springs, Colorado
Medical Associates of Brevard
Melbourne, Florida
University of South Florida Division of Allergy and Immunology
Tampa, Florida
Family Allergy and Asthma Center, PC
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
Research Institute of Deaconess Clinic
Evansville, Indiana
University of Iowa Asthma Center/ Hospitals & Clinics
Iowa City, Iowa
LSUHSC Allergy & Immunology
Shreveport, Louisiana
Institute for Asthman & Allergy, P.C.
Chevy Chase, Maryland
Massachusetts General Hospital
Boston, Massachusetts
The Asthma Center
St Louis, Missouri
University of Reno Nevada School of Medicine
Reno, Nevada
STARx Research Center, LLC
Edison, New Jersey
Winthrop University Hospital Clinical Trials Center
Mineola, New York
Mount Sinai School of Medicine
New York, New York
Montefiore Medical Center/Albert Einstein College of Medicine
The Bronx, New York
Allergy Partners of Western North Carolina
Asheville, North Carolina
Duke University Medical Center
Durham, North Carolina
University of Cincinnati Division of Immunology/Allergy
Cincinnati, Ohio
Optimed Research, LTD
Columbus, Ohio
Tulsa Allergy Clinic
Tulsa, Oklahoma
Baker Allergy, Asthma & Dermatology Research Center LLC
Lake Oswego, Oregon
Valley Clinical Research Center
Bethlehem, Pennsylvania
Penn State Hershey Medical Center
Hershey, Pennsylvania
Children's Hospital of Pittsburgh (of UMPC)
Pittsburgh, Pennsylvania
AARA Research Center
Dallas, Texas
University of Texas Medical Branch (UTMB)
Galveston, Texas
Texas A&M Health Science Center College of Medicine
Houston, Texas
Allergy and Asthma Research Center, P.A.
San Antonio, Texas
University of Utah
Salt Lake City, Utah
Royal Adelaide Hospital
Adelaide, Australia
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.